Magazine Article | December 1, 2022

How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing

Source: Life Science Leader

By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

Speak directly to any CGT (cell and gene therapy) executive, and you’re likely to hear about the two things that, in some way, keep them up at night when it comes to their jobs — time and cost. I asked some of the cell and gene therapy sector’s most quantifiably successful leaders, Christine (Chris) Fox, president at Novartis Gene Therapies; Karen Kozarsky, Ph.D., founder and CSO at SwanBio Therapeutics; and Vaishali Shukla, VP, quality commercial manufacturing at Kite Pharma, to weigh in on a topic that affects every CGT company — manufacturing. Here, you’ll glean a better understanding of how to drive down COGS and expedite commercial- scale manufacturing in the CGT space.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader